GenomeDx Biosciences announced today that it has expanded an existing research agreement with the Mayo Clinic. The expanded agreement includes exclusive license to certain Mayo developed intellectual property along with exclusivity covering co-developed intellectual property…"Access to the Mayo Clinic's comprehensive cohort of samples from patients classified as high risk for metastatic disease and the involvement of Mayo Clinic researchers has been essential to the development of Decipher," said Doug Dolginow, M.D., Chief Executive Officer of GenomeDx.

Wall Street Journal

Tags: Business Relations, Decipher, Dr. Doug Dolginow, GenomeDx Biosciences, Industry News & Competitive Intelligence, intellectual property, metastatic disease, Research, research agreement, Wall Street Journal